No DLTs occurred; therefore, enrollment proceeded for patients with unresectable/metastatic melanoma and primary resistance (cohort 1) or acquired resistance (cohort 2) to one to two prior lines of anti-PD-1 therapy. The gene discussed is PDCD1; the disease is metastatic melanoma.